Healthcare
Ligand Pharmaceuticals Incorporated(LGND)
Live Price
Offline$274.88
+4.46% today
Window Change
+20.29%
Window
May 5, 2026 โ Jun 23, 2026
- Market Cap
- $4.68B
- Revenue Growth
- +60.4%
- EPS Growth
- +3027.3%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 29 bars ยท May 5, 2026 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Ligand Pharmaceuticals Incorporated (LGND) is a Healthcare stock with a market cap of $4.68B and listed on NASDAQ. The stock last traded around $274.88 and up 20.3% across the available one-year price window (May 5, 2026 โ Jun 23, 2026). Baseline metrics include revenue growth of +60.4%, EPS growth of +3027.3%, a dividend yield of 0.0%. What stands out right now is revenue +60.4%, EPS +3027.3%, free cash flow -36.8% with operating margin 17.6% and ROIC 2.4%. Valuation already assumes a fairly strong business story at P/E 37.2 and price/sales 17.5. Stock Foundry combines LGND price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+60.4% vs +7.6% peer median
Operating Margin
Near sector median
+17.6% vs +19.4% peer median
P/E
Near sector median
37.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +60.4% and EPS at +3027.3%, with operating margin around 17.6%.
Benchmark Edge
LGND vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LGND
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LGND Max Drawdown
-9.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LGND and SPY.
Company Overview
Ligand Pharmaceuticals Incorporated
NASDAQ Global Market
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
- Leadership
- Todd C. Davis
- IPO Date
- Nov 18, 1992
- Employees
- 68
- Street Address
- 5980 Horton Street
- Mailing
- Jupiter, CA, 94608
- Region
- Jupiter, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 550 7500
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.2
- EV/EBITDA
- 25.3
- Price/Sales
- 17.5
- Price/Book
- 4.6
Growth
- Revenue
- +60.4%
- EPS
- +3027.3%
- Free Cash Flow
- -36.8%
Profitability
- Gross Margin
- 97.5%
- Operating Margin
- 17.6%
- Net Margin
- 46.4%
- ROE
- 13.9%
- ROIC
- 2.4%
Balance Sheet
- Debt/Equity
- 0.44
- Current Ratio
- 22.23
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.